Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. Cancer 2017 Apr 15;123(8):1416-1423
Date
11/29/2016Pubmed ID
27893933Pubmed Central ID
PMC5384862DOI
10.1002/cncr.30454Scopus ID
2-s2.0-85006106915 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients.
METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT.
RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α = .77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity.
CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416-1423. © 2016 American Cancer Society.
Author List
Syrjala KL, Sutton SK, Jim HS, Knight JM, Wood WA, Lee SJ, Jacobsen PB, Abidi MH, Yi JCAuthor
Jennifer M. Knight MD, MS Associate Professor in the Psychiatry and Behavioral Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Aged
Emotions
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Neoplasms
Psychometrics
Quality of Life
Socioeconomic Factors
Stress, Psychological
Surveys and Questionnaires
Transplantation, Homologous
Young Adult
